Navigation Links
Dana-Farber Cancer Institute Chooses MicroStrategy for Clinical Operations and Clinical Research Reporting Applications
Date:1/21/2009

MCLEAN, Va., Jan. 21 /PRNewswire-FirstCall/ -- MicroStrategy(R) Incorporated (Nasdaq: MSTR), a leading worldwide provider of business intelligence (BI) software, today announced that Dana-Farber Cancer Institute has selected the MicroStrategy Business Intelligence Platform(TM) for clinical operations and clinical research reporting applications. Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States.

Dana-Farber will use MicroStrategy for its clinical operations reporting application, which will be used by clinic managers, nurses, disease program administrators, and schedulers to improve their ability to manage patient flow through clinical areas, reduce wait times, optimize clinical processes like pharmacy dispenses and medical records management, and monitor staffing levels. Clinical research assistants, statisticians, doctors, and clinical researchers will use the MicroStrategy-based clinical research reporting application for insights into data that will help them write research papers and grants, identify patients for clinical studies, and better understand treatment outcomes.

"We selected MicroStrategy because we needed a fully integrated business intelligence platform that was reliable, scalable, and easy to use," said John Orechia, Clinical and Research Reporting Team Leader of Dana-Farber Cancer Institute. "With MicroStrategy's robust reporting and intuitive Web interface, our personnel will have access to the information they need to make essential decisions for our organization and our patients."

"We are proud to support Dana-Farber Cancer Institute and its multiple reporting applications," said MicroStrategy's COO Sanju Bansal. "Organizations across the healthcare industry rely on MicroStrategy to analyze and improve operations, service quality, and resource utilization."

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.

About MicroStrategy

Founded in 1989, MicroStrategy is a global leader in business intelligence (BI) technology. MicroStrategy provides integrated reporting, analysis, and monitoring software that helps leading organizations worldwide make better business decisions every day. Companies choose MicroStrategy for its advanced technical capabilities, sophisticated analytics, and superior data and user scalability. More information about MicroStrategy (Nasdaq: MSTR) is available at www.microstrategy.com.

MicroStrategy and MicroStrategy Business Intelligence Platform are either trademarks or registered trademarks of MicroStrategy Incorporated in the United States and certain other countries. Other product and company names mentioned herein may be the trademarks of their respective owners.

    Contact:
    Wende Cover
    MicroStrategy Incorporated
    703-770-1646
    wcover@microstrategy.com


'/>"/>
SOURCE MicroStrategy Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
2. Dana-Farber Cancer Institute Completes Deployment of MedAptus Infusion Services Module
3. Dana-Farber Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
4. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
5. Survival differences by race most apparent in advanced stages of breast cancer
6. MRI finds breast cancer before it becomes dangerous
7. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
8. Pathway links inflammation, angiogenesis and breast cancer
9. Radiologists encouraged to look beyond cancer for clinically unseen diseases
10. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
11. Immune deficiency linked to a type of eye cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Gym Source, America’s leading ... new showroom at South Dixie Hwy in Miami, FL. , “We are elated to ... “The new innovative in-store concept is designed to give clients a seamless and motivating ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... political/social/economic events, Dr. Carol Francis re-releases powerfully uplifting interview with medical expert and ... help everyone endure and pass through tough times, Dr. Bernie Siegel energizes listeners ...
(Date:1/17/2017)... Florida (PRWEB) , ... January 17, 2017 , ... Kevin ... Producers of AsSeenOnTV.pro will be featuring DRTV campaigns regarding the topic of Beauty and ... become a better version of themselves. What better way to commit to these changes ...
(Date:1/17/2017)... ... January 17, 2017 , ... Achieve ... Desert, is opening a new office in San Clemente, California this month. Achieve ... in Southern California, successfully treating individuals struggling with major depression. Depression impacts over ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... Center joined the Peoples Health network on Dec. 1, 2016. Peoples Health, ... “JenCare Senior Medical Center is an exciting addition to our provider network, and ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Philadelphia Pediatric Medical Device Consortium (PPDC) has announced seed grants ... Consortium chose those companies from eight finalists in a ... The devices under development are a powered orthotic arm brace ... system for emergency situations and a device that gradually corrects ... ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... company specializing in the development and commercialization of regenerative ... and organs, recently reported the Company,s operating results for ... As the Company described in its recent ... year of substantial accomplishments. The Company,s contract laboratory completed ...
(Date:1/18/2017)... SAN DIEGO , Jan. 18, 2017 /PRNewswire/ ... and innovative products to treat a variety of ... its lead compound DMT210, in a Phase 2 ... specifically developed to downregulate the proinflammatory cytokines in ... seen in acne rosacea. This ...
Breaking Medicine Technology: